A Proteomic Approach for the Identification of Vascular Markers of Liver Metastasis

被引:38
作者
Borgia, Beatrice [1 ]
Roesli, Christoph [1 ]
Fugmann, Tim [1 ]
Schliemann, Christoph [1 ]
Cesca, Marta [2 ]
Neri, Dario [1 ]
Giavazzi, Raffaella [2 ]
机构
[1] ETH, Inst Pharmaceut Sci, Dept Chem & Appl Biosci, Zurich, Switzerland
[2] Mario Negri Inst Pharmacol Res, Dept Oncol, Lab Biol & Treatment Metastasis, I-20157 Milan, Italy
基金
瑞士国家科学基金会;
关键词
VIVO PROTEIN BIOTINYLATION; ED-B DOMAIN; RETICULUM-CELL SARCOMA; IN-VIVO; MONOCLONAL-ANTIBODY; CANCER THERAPEUTICS; LUNG-CANCER; TUMOR; FIBRONECTIN; ANTIGENS;
D O I
10.1158/0008-5472.CAN-09-2939
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vascular proteins expressed at liver metastasis sites could serve as prognostic markers or as targets for pharmacodelivery applications. We employed a proteomic approach to define such proteins in three syngeneic mouse models of liver metastasis. Vascular structures were biotinylated in vivo by a terminal perfusion technique, followed by mass spectrometric analysis of accessible biotinylated proteins. In this manner, we identified 12 proteins for which expression was selectively associated with liver metastasis, confirming this association by tissue immunofluorescence or in vivo localization with radiolabeled antibodies. In summary, our findings identify vascular proteins that may have prognostic or drug-targeting use in addressing liver metastases, a common issue in many advanced cancers. Cancer Res; 70(1); 309-18. (C)2010 AACR.
引用
收藏
页码:309 / 318
页数:10
相关论文
共 42 条
[1]   Monoclonal antibody therapy of cancer [J].
Adams, GP ;
Weiner, LM .
NATURE BIOTECHNOLOGY, 2005, 23 (09) :1147-1157
[2]   A MURINE OVARIAN TUMOR WITH UNIQUE METASTASIZING CAPACITY [J].
ALESSANDRI, G ;
GIAVAZZI, R ;
FALAUTANO, P ;
SPREAFICO, F ;
GARATTINI, S ;
MANTOVANI, A .
EUROPEAN JOURNAL OF CANCER, 1981, 17 (06) :651-&
[3]   EFFECT OF INTERLEUKIN-1-BETA ON METASTASIS FORMATION IN DIFFERENT TUMOR SYSTEMS [J].
BANI, MR ;
GAROFALO, A ;
SCANZIANI, E ;
GIAVAZZI, R .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (02) :119-123
[4]   Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin [J].
Borsi, L ;
Balza, E ;
Bestagno, M ;
Castellani, P ;
Carnemolla, B ;
Biro, A ;
Leprini, A ;
Sepulveda, J ;
Burrone, O ;
Neri, D ;
Zardi, L .
INTERNATIONAL JOURNAL OF CANCER, 2002, 102 (01) :75-85
[5]  
Bosslet K, 1998, CANCER RES, V58, P1195
[6]   Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C [J].
Brack, Simon S. ;
Silacci, Michela ;
Birchler, Manfred ;
Neri, Dario .
CLINICAL CANCER RESEARCH, 2006, 12 (10) :3200-3208
[7]   Antibody-drug conjugates for cancer therapy [J].
Carter, Paul J. ;
Senter, Peter D. .
CANCER JOURNAL, 2008, 14 (03) :154-169
[8]   Potent antibody therapeutics by design [J].
Carter, PJ .
NATURE REVIEWS IMMUNOLOGY, 2006, 6 (05) :343-357
[9]   Caveolae: Mining little caves for new cancer targets [J].
Carver, LA ;
Schnitzer, JE .
NATURE REVIEWS CANCER, 2003, 3 (08) :571-581
[10]   A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer [J].
Castronovo, Vincent ;
Waltregny, David ;
Kischel, Philippe ;
Roesli, Christoph ;
Elia, Giuliano ;
Rybak, Jascha-N. ;
Neri, Dario .
MOLECULAR & CELLULAR PROTEOMICS, 2006, 5 (11) :2083-2091